Characterization of Korean Colorectal Cancer Reveals Novel Driver Gene and Clinically Relevant Mutations

Abstract

Colorectal cancer (CRC) ranks as the third leading cause of cancer-related deaths worldwide, characterized by genomic heterogeneity arising from ethnic and interindividual differences. Producing region-specific data to characterize ethnic-specific somatic mutations is essential for advancing CRC research. Additionally, accurate somatic mutation detection requires paired tissue analyses to account for interindividual diversity. This study aims to highlight the importance of ethnic diversity in shaping CRC's genomic landscape and emphasize the necessity for region-specific data to refine diagnostic and therapeutic approaches. This study emphasizes the need for region-specific data by analyzing an unprecedented 197 paired samples from the Korean CRC cohort through whole-genome sequencing. We identified 78 potential driver genes. Notably, CBWD5, LRRIQ3, TRIM64B, SPINK5, and ZNRF2 were linked to recurrence, presenting potential therapeutic targets. Our analysis revealed 30 mutational hotspots, with significant variants in KRAS (25%, G12A, G12D, G12V), MAP1A (12%, V2300G), and TP53 (8%, R175H). We identified a significant co-occurrence between KRAS 12 mutation and PIK3CA 545 mutation. Our findings demonstrate potential driver genes and mutational hotspots associated with CRC patient, characterizing the mutational landscape related to clinical characteristics. Significantly advancing our understanding of CRC's heterogeneous nature, this study lays a solid foundation for devising more efficacious management strategies.

Keywords

colorectal cancer / microsatellite instability / mutational hotspots / tumor mutational burden / whole-genome sequencing

References

[1] M. J. Kang, Y. J. Won, J. J. Lee, et al., “Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019,” Cancer Research and Treatment: Official Journal of Korean Cancer Association 54, no. 2 (2022): 330–344.

[2] Y. H. Xie, Y. X. Chen, and J. Y. Fang, “Comprehensive Review of Targeted Therapy for Colorectal Cancer,” Signal Transduct Target Ther 5, no. 1 (2020): 22.

[3] D. K. Rex, C. R. Boland, J. A. Dominitz, et al., “Colorectal Cancer Screening: Recommendations for Physicians and Patients From the US Multi-Society Task Force on Colorectal Cancer,” Gastroenterology 153, no. 1 (2017): 307–323.

[4] N. Keum and E. Giovannucci, “Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies,” Nature Reviews Gastroenterology & Hepatology 16, no. 12 (2019): 713–732.

[5] J. Sánchez-Gundín, A. M. Fernández-Carballido, L. Martínez-Valdivieso, D. Barreda-Hernández, and A. I. Torres-Suárez, “New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer,” International Journal of Medical Sciences 15, no. 7 (2018): 659.

[6] E. P. van der Stok, M. C. Spaander, D. J. Grünhagen, C. Verhoef, and E. J. Kuipers, “Surveillance After Curative Treatment for Colorectal Cancer,” Nature Reviews Clinical Oncology 14, no. 5 (2017): 297–315.

[7] A. M. Wolf, E. T. Fontham, T. R. Church, et al., “Colorectal Cancer Screening for Average-risk Adults: 2018 Guideline Update From the American Cancer Society,” CA: a Cancer Journal for Clinicians 68, no. 4 (2018): 250–281.

[8] K. G. Brown, M. J. Solomon, K. Mahon, and S. O'Shannassy, “Management of Colorectal Cancer,” Bmj 366 (2019).

[9] R. Labianca, B. Nordlinger, G. Beretta, et al., “Early Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up,” Annals of Oncology 24 (2013): vi64–vi72.

[10] W. A. Messersmith, “NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer,” Journal of the National Comprehensive Cancer Network 17, no. 5.5 (2019): 599–601.

[11] E. Van Cutsem, A. Cervantes, B. Nordlinger, D. Arnold, and E. G. W. Group, “Metastatic Colorectal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up,” Annals of Oncology 25 (2014): iii1–iii9.

[12] G. M. Blumenthal, E. Mansfield, and R. Pazdur, “Next-Generation Sequencing in Oncology in the Era of Precision Medicine,” JAMA Oncology 2, no. 1 (2016): 13–14.

[13] C. Network, “Comprehensive Molecular Profiling of Lung Adenocarcinoma,” Nature 511, no. 7511 (2014):543.

[14] J. Armenia, S. A. Wankowicz, D. Liu, et al., “The Long Tail of Oncogenic Drivers in Prostate Cancer,” Nature Genetics 50, no. 5 (2018): 645–651.

[15] A.-M. Patch, E. L. Christie, and D. Etemadmoghadam, “Whole–genome Characterization of Chemoresistant Ovarian Cancer,” Nature 521, no. 7553 (2015): 489–494.

[16] S. A. Jeon, Y. J. Ha, J.-H. Kim, et al., “Genomic and Transcriptomic Analysis of Korean Colorectal Cancer Patients,” Genes & Genomics 44, no. 8 (2022): 967–979.

[17] J. E. Kim, J. Choi, C.-O. Sung, et al., “High Prevalence of TP53 Loss and Whole-genome Doubling in Early-onset Colorectal Cancer,” Experimental & Molecular Medicine 53, no. 3 (2021): 446–456.

[18] A. Garofalo, L. Sholl, B. Reardon, et al., “The Impact of Tumor Profiling Approaches and Genomic Data Strategies for Cancer Precision Medicine,” Genome Med 8, no. 1 (2016): 79.

[19] X. Huang, D. F. Stern, and H. Zhao, “Transcriptional Profiles From Paired Normal Samples Offer Complementary Information on Cancer Patient Survival–evidence From TCGA Pan-cancer Data,” Scientific Reports 6, no. 1 (2016): 20567.

[20] N. Goel, D. Y. Kim, J. A. Guo, D. Zhao, B. A. Mahal, and M. Alshalalfa, “Racial Differences in Genomic Profiles of Breast Cancer,” JAMA Network Open 5, no. 3 (2022): e220573–e220573.

[21] R. A. Oyer, P. Hurley, L. Boehmer, et al., “Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement,” Journal of Clinical Oncology 40, no. 19 (2022): 2163–2171.

[22] A. N. Holowatyj, W. Wen, T. Gibbs, et al., “Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations Among Patients With Early-onset Colorectal Cancer,” Cancer Discovery 13, no. 3 (2023): 570–579.

[23] A. Oni-Orisan, Y. Mavura, Y. Banda, T. A. Thornton, and R. Sebro, Embracing Genetic Diversity to Improve Black Health (Mass Medical Soc, 2021): 1163–1167.

[24] N. Ansari-Pour, Y. Zheng, T. F. Yoshimatsu, et al., “Whole-genome Analysis of Nigerian Patients With Breast Cancer Reveals Ethnic-driven Somatic Evolution and Distinct Genomic Subtypes,” Nature Communications 12, no. 1 (2021): 6946.

[25] C. M. Aldrighetti, A. Niemierko, E. Van Allen, H. Willers, and S. C. Kamran, “Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies,” JAMA Network Open 4, no. 11 (2021): e2133205–e2133205.

[26] L. D. Wood, D. W. Parsons, S. Jones, et al., “The Genomic Landscapes of human Breast and Colorectal Cancers,” Science 318, no. 5853 (2007): 1108–1113.

[27] N. L. Nehrt, T. A. Peterson, D. Park, and M. G. Kann, Domain Landscapes of Somatic Mutations in Cancer (Springer, 2012): 1–13.

[28] B. Vogelstein and K. W. Kinzler, “Cancer Genes and the Pathways They Control,” Nature Medicine 10, no. 8 (2004):789–799.

[29] F. Sanchez-Vega, M. Mina, J. Armenia, et al., “Oncogenic Signaling Pathways in the Cancer Genome Atlas,” Cell 173, no. 2 (2018): 321–337.e10.

[30] M. F. Muller, A. E. Ibrahim, and M. J. Arends, “Molecular Pathological Classification of Colorectal Cancer,” Virchows Archiv 469, no. 2 (2016): 125–134.

[31] Cancer Genome Atlas N. Comprehensive Molecular Characterization of human Colon and Rectal Cancer. Nature 2012;487(7407):330–337.

[32] C. Esteban-Jurado, D. Gimenez-Zaragoza, and J. Munoz, “POLE and POLD1 Screening in 155 Patients With Multiple Polyps and Early-onset Colorectal Cancer,” Oncotarget 8, no. 16 (2017): 26732–26743.

[33] H. Chen, R. Y. Jiang, Z. Hua, et al., “Comprehensive Analysis of Gene Mutations and Mismatch Repair in Chinese Colorectal Cancer Patients,” World Journal of Gastrointestinal Oncology 16, no. 6 (2024): 2673–2682.

[34] S. A. Jeon, Y. J. Ha, J. H. Kim, et al., “Genomic and Transcriptomic Analysis of Korean Colorectal Cancer Patients,” Genes Genomics 44, no. 8 (2022): 967–979.

[35] J. Choi, S. Kim, J. Kim, et al., “A Whole-genome Reference Panel of 14,393 Individuals for East Asian Populations Accelerates Discovery of Rare Functional Variants,” Science Advances 9, no. 32 (2023): eadg6319.

[36] N. Papadimitriou, A. Kim, E. S. Kawaguchi, et al., “Genome-wide Interaction Study of Dietary Intake of Fibre, Fruits, and Vegetables With Risk of Colorectal Cancer,” EBioMedicine (2024): 104.

[37] A. B. Popejoy and S. M. Fullerton, “Genomics Is Failing on Diversity,” Nature 538, no. 7624 (2016): 161–164.

[38] J. Guerra, C. Pinto, D. Pinto, et al., “POLE Somatic Mutations in Advanced Colorectal Cancer,” Cancer Medicine 6, no. 12 (2017): 2966–2971.

[39] A. J. Cornish, A. J. Gruber, B. Kinnersley, et al., “The Genomic Landscape of 2,023 Colorectal Cancers,” Nature 633, no. 8028 (2024): 127–136.

[40] A. S. Jumaah, M. M. Salim, H. S. Al-Haddad, K. A. McAllister, and A. A. Yasseen, “The Frequency of POLE-mutation in Endometrial Carcinoma and Prognostic Implications: A Systemic Review and Meta-analysis,” J Pathol Transl Med 54, no. 6 (2020): 471–479.

[41] E. Castellucci, T. He, D. Y. Goldstein, B. Halmos, and J. Chuy, “DNA Polymerase Varepsilon Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity,” The Oncologist 22, no. 5 (2017): 497–502.

[42] X. Ma, L. Dong, X. Liu, K. Ou, and L. Yang, “POLE/POLD1 Mutation and Tumor Immunotherapy,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 216.

[43] A. Keshinro, C. Vanderbilt, J. K. Kim, et al., “Tumor-infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer,” JCO Precision Oncology 5 (2021): 817–826.

[44] W. Shaib, R. Mahajan, and B. El-Rayes, “Markers of Resistance to Anti-EGFR Therapy in Colorectal Cancer,” J Gastrointest Oncol 4, no. 3 (2013): 308–318.

[45] Q. Ma, W. Zhang, K. Wu, and L. Shi, “The Roles of KRAS in Cancer Metabolism, Tumor Microenvironment and Clinical Therapy,” Molecular cancer 24, no. 1 (2025): 14.

[46] Z. L. Ye, M. Z. Qiu, T. Tang, et al., “Gene Mutation Profiling in Chinese Colorectal Cancer Patients and Its Association With Clinicopathological Characteristics and Prognosis,” Cancer Med-Us 9, no. 2 (2020): 745–756.

[47] M. E. E. Fernandez, G. Argiles, J. Matito, et al., “Coexisting KRAS and PIK3CA Exon 20 Mutations as a Potential Poor-prognosis Factor in Metastatic Colorectal Cancer (mCRC),” Journal of Clinical Oncology 32, no. 15 (2014).

[48] D. L. Jardim, J. J. Wheler, K. Hess, et al., “FBXW7 mutations in Patients With Advanced Cancers: Clinical and Molecular Characteristics and Outcomes With mTOR Inhibitors,” PLoS ONE 9, no. 2 (2014): e89388.

[49] L. W. Guo, Y. J. Wang, W. X. Yang, et al., “Molecular Profiling Provides Clinical Insights into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis,” Gastroenterology 165, no. 2 (2023).

[50] S. K. Nam, S. Yun, J. Koh, et al., “BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers With Distant Metastasis,” PLoS ONE 11, no. 3 (2016): e0151865.

[51] E. K. Wei, E. Giovannucci, K. Wu, et al., “Comparison of Risk Factors for Colon and Rectal Cancer,” International Journal of Cancer 108, no. 3 (2004): 433–442.

[52] B. Dhabhai, A. Sharma, J. Maciaczyk, and T. C. Dakal, “X-Linked Tumor Suppressor Genes Act as Presumed Contributors in the Sex Chromosome-Autosome Crosstalk in Cancers,” Cancer Investigation 40, no. 2 (2022): 103–110.

[53] D. Wang, L. Tang, Y. Wu, et al., “Abnormal X Chromosome Inactivation and Tumor Development,” Cellular and Molecular Life Sciences 77, no. 15 (2020): 2949–2958.

[54] K. B. Myant, P. Cammareri, M. C. Hodder, et al., “HUWE 1 Is a Critical Colonic Tumour Suppressor Gene That Prevents MYC Signalling, DNA Damage Accumulation and Tumour Initiation,” EMBO Molecular Medicine 9, no. 2 (2017): 181–197.

[55] C. Garrett, D. Steffens, M. Solomon, and C. Koh, “Early-onset Colorectal Cancer: Why It Should be High on Our List of Differentials,” Anz Journal of Surgery 92, no. 7-8 (2022): 1638–1643.

[56] A. C. Hamilton, F. J. Bannon, P. D. Dunne, et al., “Distinct Molecular Profiles of Sporadic Early-Onset Colorectal Cancer: A Population-Based Cohort and Systematic Review,” Gastro Hep Adv 2, no. 3 (2023): 347–359.

[57] J. Tang, W. Peng, C. Tian, et al., “Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer: A Case Controlled Study,” Int J Surg 110, no. 8 (2024): 4559–4570.

[58] J. L. Hu, W. Wang, and X. L. Lan, “CAFs Secreted Exosomes Promote Metastasis and Chemotherapy Resistance by Enhancing Cell Stemness and Epithelial-mesenchymal Transition in Colorectal Cancer,” Molecular cancer 18, no. 1 (2019): 91.

[59] W. M. Grady and J. M. Carethers, “Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis,” Gastroenterology 135, no. 4 (2008): 1079–1099.

[60] A. Zinkeng, F. L. Taylor, S. H. Cheong, H. Song, and J. L. Merchant, “Early Onset Colorectal Cancer: Molecular Underpinnings Accelerating Occurrence,” Cell Mol Gastroenterol Hepatol 19, no. 2 (2025): 101425.

[61] J. Bian, M. Dannappel, C. Wan, and R. Firestein, “Transcriptional Regulation of Wnt/Beta-Catenin Pathway in Colorectal Cancer,” Cells 9, no. 9 (2020).

[62] N. Kothari, J. K. Teer, A. M. Abbott, et al., “Increased Incidence of FBXW7 and POLE Proofreading Domain Mutations in Young Adult Colorectal Cancers,” Cancer 122, no. 18 (2016): 2828–2835.

[63] A. Zehir, R. Benayed, R. H. Shah, et al., “Erratum: Mutational Landscape of Metastatic Cancer Revealed From Prospective Clinical Sequencing of 10,000 Patients,” Nature Medicine 23, no. 8 (2017): 1004.

[64] S. Yoon, J. H. Choi, S. J. Kim, et al., “EPHB6 mutation Induces Cell Adhesion-mediated Paclitaxel Resistance via EPHA2 and CDH11 Expression,” Experimental & Molecular Medicine 51, no. 6 (2019): 1–12.

[65] A. R. Brannon, E. Vakiani, B. E. Sylvester, et al., “Comparative Sequencing Analysis Reveals High Genomic Concordance Between Matched Primary and Metastatic Colorectal Cancer Lesions,” Genome Biology 15, no. 8 (2014).

[66] E. Vakiani, M. Janakiraman, R. Shen, et al., “Comparative Genomic Analysis of Primary versus Metastatic Colorectal Carcinomas,” Journal of Clinical Oncology 30, no. 24 (2012): 2956–2962.

[67] J. H. Kim, J. H. Park, J. Lee, et al., “Ultra-Low Level Somatic Mutations and Structural Variations in Focal Cortical Dysplasia Type II,” Annals of Neurology 93, no. 6 (2023): 1082–1093.

[68] B. Lee, D. M. Lim, K. Shin, et al., “Time-dependent Reduction of Somatic Variants in Lichen Striatus as Evidence for the Clearance of Mutated Skin Cells,” Journal of the American Academy of Dermatology (2025).

[69] C. H. Nam, J. Youk, J. Y. Kim, et al., “Widespread Somatic L1 Retrotransposition in Normal Colorectal Epithelium,” Nature 617, no. 7961 (2023): 540–547.

[70] A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, “Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer,” Genome Research 28, no. 11 (2018): 1747–1756.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.